EUVIMEDEUVIMED entdecken
Crossref

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center

Lena Papadakis, Tayler Stander, Jacqueline Mombourquette, Christopher J Richards, Lael M Yonker, Brenden Lawton, Margot Hardcastle, Julia Zweifach, Leonard Sicilian, Lindsay Bringhurst, Isabel P Neuringer

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.27382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Lena Papadakis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Division, Massachusetts General Hospital for Children, MGH Cystic Fibrosis Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NHLBI NIH HHS, The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The benefits of Elexecaftor‐Tezacaftor‐Ivacaftor (ETI) therapy on the health and wellbeing of people with CF (pwCF) are well documented. Since approval, however, a growing number of potential side effects have emerged in reports from clinical practice. With current understanding of ETI tolerability limited to data from clinical trials, the prevalence of side effects and their impact on care decision making remains poorly categorized.

Methods

A 10‐question survey was developed and distributed to patients 18 years or older who were treated at the Massachusetts General Hospital CF centers. Reports of side effects were measured across 12 distinct categories, and dose adjustments and discontinuation due to side effects were collected. If a patient reported no side effects, they did not have to complete the entire survey.

Results

Among 92 respondents initiated on ETI, 51 respondents (55.4%) reported potential side effects and 41 (44.5%) respondents reported no adverse events. The most commonly reported side effects were mental health, changes in appearance, and gastrointestinal complaints, which were reported by 22.8%, 30.4%, and 21.7% of patients, respectively. Eighteen (19.6%) respondents modified their dosing in response to side effects, and six discontinued treatment permanently (6.52%) due to persistent side effects.

Conclusions

Responses demonstrated marked heterogeneity, with most respondents reporting at least one side effect following initiation. Dose modification was commonly utilized to mitigate adverse effects, however few respondents had to discontinue treatment. These findings demonstrate the importance of monitoring for potential drug‐related side effects of ETI in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesIndolesPyridinesPyrrolidinesPyrazolesHumansDrug CombinationsMaleFemaleAdultAdolescentYoung AdultSurveys and QuestionnairesMiddle AgedQuinolines

Stichwörter der Autor:innen

CFTR modulatoradverse eventcystic fibrosispatient‐reported outcomes

Substanzen

AminophenolsDrug CombinationsBenzodioxolesQuinolonesIndolesPyridinesPyrrolidinesPyrazoleselexacaftor, ivacaftor, tezacaftor drug combinationtezacaftor, ivacaftor drug combination

Autor:innen und Institutionen

  • Pulmonary Division, Massachusetts General Hospital for Children, MGH Cystic Fibrosis Center, Boston, Massachusetts, USA.
  • Pulmonary Division, Massachusetts General Hospital, MGH Cystic Fibrosis center, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • The authors received no specific funding for this work.

Zitieren

APA

Papadakis, L., Stander, T., Mombourquette, J., Richards, C. J., Yonker, L. M., Lawton, B., Hardcastle, M., Zweifach, J., Sicilian, L., Bringhurst, L., & Neuringer, I. P. (2025). Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27382

Vancouver

Papadakis L, Stander T, Mombourquette J, Richards CJ, Yonker LM, Lawton B, et al. Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27382

BibTeX
@article{Papadakis2025,
  author = {Papadakis, Lena and Stander, Tayler and Mombourquette, Jacqueline and Richards, Christopher J and Yonker, Lael M and Lawton, Brenden and Hardcastle, Margot and Zweifach, Julia and Sicilian, Leonard and Bringhurst, Lindsay and Neuringer, Isabel P},
  title = {Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.27382}
}
Kostenlos starten →